Sibrotuzumab
N/A
Report date: 2026/03/23 20:03:44
Base Information
Drug NameSibrotuzumab
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International GmbhLudwig Institute For Cancer Research
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgNational Cancer Institute
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksWikipedia